564 related articles for article (PubMed ID: 6232320)
1. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
2. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
4. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
[TBL] [Abstract][Full Text] [Related]
5. Importance of the integrity of the inter-heavy-chain disulphide bond of rabbit IgG in the activation of the alternative pathway of human complement by the F(ab')2 region of rabbit IgG antibody in immune aggregates.
Gadd KJ; Reid KB
Immunology; 1981 Jan; 42(1):75-82. PubMed ID: 6780451
[TBL] [Abstract][Full Text] [Related]
6. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
Gadd KJ; Reid KB
Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
[TBL] [Abstract][Full Text] [Related]
7. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
Antón LC; Alcolea JM; Sánchez-Corral P; Marqués G; Sánchez A; Vivanco F
Biochem J; 1989 Feb; 257(3):831-8. PubMed ID: 2784671
[TBL] [Abstract][Full Text] [Related]
8. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
9. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
10. Breakdown of C3 covalently bound to F(ab')2 immune complexes after complement activation by the alternative pathway.
Antón LC; Alcolea JM; Marqués G; Sánchez-Corral P; Vivanco F
Complement; 1986; 3(2):53-62. PubMed ID: 3769463
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of complement amplification by F(ab')(2)-containing immune complexes and naturally occurring anti-hinge antibodies, possible role in systemic inflammation.
Lutz HU; Fumia S
Autoimmun Rev; 2008 Jun; 7(6):508-13. PubMed ID: 18558371
[TBL] [Abstract][Full Text] [Related]
12. Solubilization of immune precipitates by six isolated alternative pathway proteins.
Fujita T; Takata Y; Tamura N
J Exp Med; 1981 Dec; 154(6):1743-51. PubMed ID: 6459396
[TBL] [Abstract][Full Text] [Related]
13. The covalent interaction of C3 with IgG immune complexes.
Vivanco F; Muñoz E; Vidarte L; Pastor C
Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.
Zhang W; Lachmann PJ
Immunology; 1994 Jan; 81(1):137-41. PubMed ID: 8132210
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
Fischer E; Appay MD; Cook J; Kazatchkine MD
J Immunol; 1986 Feb; 136(4):1373-7. PubMed ID: 2418113
[TBL] [Abstract][Full Text] [Related]
16. Activation of rat complement by soluble and insoluble rat IgA immune complexes.
Rits M; Hiemstra PS; Bazin H; Van Es LA; Vaerman JP; Daha MR
Eur J Immunol; 1988 Dec; 18(12):1873-80. PubMed ID: 3220102
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
18. Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.
Aguado MT; Mannik M
Immunology; 1987 Feb; 60(2):255-60. PubMed ID: 3817872
[TBL] [Abstract][Full Text] [Related]
19. The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.
Muñoz E; Vidarte L; Casado MT; Pastor C; Vivanco F
Int Immunol; 1998 Feb; 10(2):97-106. PubMed ID: 9580208
[TBL] [Abstract][Full Text] [Related]
20. Human erythrocytes inhibit complement-mediated solubilization of immune complexes.
Dorval BL; Cosio FG; Birmingham DJ; Hebert LA
J Immunol; 1989 Apr; 142(8):2721-7. PubMed ID: 2522967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]